Clinical Trials Browser

NIH × MK 2206 × Breast × Clear all

NCT01277757 2018-12-19

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Phase 2 Completed

30 enrolled 7 charts

Breast Neoplasms

NCT01344031 2018-07-23

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast Neoplasms

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Terminated

12 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01263145 2017-08-25

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01281163 2015-08-27

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male